Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design

Tohru Minamino(Juntendo University), Yasuchika Takeishi(Fukushima Medical University), Masafumi Yano(Yamaguchi University), Takeshi Mitsuhashi(Star General Hospital), Keiko Ota(Niigata University Medical and Dental Hospital), Ritsushi Kato(Sakakibara Hospital), Yoshihiro Morino(Iwate Medical University), Wataru Shimizu(Nippon Medical School Hospital), Masaki Ieda(University of Tsukuba), Kazuomi Kario(University of Pennsylvania), Kenichi Tsujita(Kumamoto University), Hisako Yoshida(Saga University), Koji Maemura(Nagasaki University), Toyoaki Murohara(Nagoya University), Toshihisa Anzai(Hokkaido University), Tetsuji Miura(Sapporo Medical University), Hiroshi Tada(University of Fukui), Kenichi Iijima(Tachikawa Medical Center), Shinichi Niwano(Kitasato University), Koichi Node(Saga University), Kenji Andò(Kokura Memorial Hospital), Ippei Shimizu(Boston University), Kengo Kusano(Northwestern University), Takeshi Kato(Kanazawa University), Shinya Fujiki(Niigata University), Yoshihisa Nakagawa(Shiga University of Medical Science), Shigeto Naito(Gunma Prefectural Cardiovascular Center), Takeshi Kimura(Municipal Hirakata City Hospital), Takahiro Tanaka(Niigata University Medical and Dental Hospital), Kazuyoshi Takahashi(Hirosaki University), Hirofumi Tomita, Yoshifusa Aizawa(Tachikawa Medical Center), Masafumi Watanabe(Yamagata University), Daisuke Izumi(Niigata University), Nobuhisa Hagiwara(Tokyo Women's Medical University), Kazuyuki Ozaki, Masaaki Okabe(Tachikawa Medical Center), Yusuke Kondo(University of Tsukuba), Nobutaka Kitamura(Niigata University Medical and Dental Hospital), Junichi Nitta(Sapporo Medical University)
Diabetes Therapy
September 23, 2020
Cited by 21


Related Papers